Vildagliptin-d7

Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

Product Specifications

CAS Number

[1133208-42-0]

Product Name Alternative

LAF237-d7; NVP-LAF 237-d7

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Solubility

10 mM in DMSO

Smiles

[2H]C1([2H])C([2H])([2H])C([2H])([2H])[C@@]([2H])(C#N)N1C(CNC2(C3)CC4(O)CC3CC(C4)C2)=O

Molecular Formula

C17H18D7N3O2

Molecular Weight

310.44

Precautions

P264-P270-P330-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[3]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.